Lung functional marker in IPF model
We would like to introduce a non-invasive biomarkers for Idiopathic Pulmonary Fibrosis (IPF) disease models.
In lung diseases such as idiopathic pulmonary fibrosis, lung function is evaluated along with CT and histopathological analysis of the lung. In the case of mice, evaluation of lung function is not easy to perform due to the complexity of the procedure and the need for specialized equipment. For this reason, various molecules are being evaluated for their usefulness as biomarkers.
Among them, Matrix Metalloproteinase-7 (MMP-7) is a molecule that is expected to become a biomarker of lung function, as its increase has been shown to correlate with decreased lung function (DLCO, FVC) in IPF patients [Rosas et al., PLoS Med., 2008].
The results of the biochemical analysis of MMP-7 in our Bleomycin (BLM)-induced IPF model are as follows.
The IPF model showed an increase in plasma MMP-7 on day 7 after BLM treatment and a further increase in MMP-7 on day 21 after BLM treatment as the disease progressed. In addition, treatment with nintedanib, which is approved by the FDA for the treatment of IPF, resulted in a decrease in MMP-7.
In addition to MMP-7, we are investigating the efficacy of non-invasive biomarkers in various disease models. We believe that this will enable us to provide our clients with pathological models with high clinical correlation.
If you have any questions, or would like to discuss any of our models and services, please contact us.